Protocol Ledger

NCT07621809 · Phase III · RECRUITING

Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden

Interventional Phase III clinical trial protocol NCT07621809 sponsored by Novartis in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-07-16 Enrollment: 570 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07621809
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)570 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07621809
Protocol FieldVerified Registry Value
NCT IdentifierNCT07621809
Consolidated Lead SponsorNovartis
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment570 participants (ESTIMATED)
Registered Start Date2026-07-16
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07621809
Hospital Research SiteLocationSite Profile
Tufts Medical CenterBoston, MAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI